Chronic lymphocytic leukemia at ASH 2017

At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory settin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanner, David, Steurer, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2018
Materias:
Short Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006235/
https://www.ncbi.nlm.nih.gov/pubmed/29983825
http://dx.doi.org/10.1007/s12254-018-0414-0
_version_ 1783332799086854144
author Wanner, David
Steurer, Michael
author_facet Wanner, David
Steurer, Michael
author_sort Wanner, David
collection PubMed
description At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia.
format Online
Article
Text
id pubmed-6006235
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-60062352018-07-04 Chronic lymphocytic leukemia at ASH 2017 Wanner, David Steurer, Michael Memo Short Review At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together with a manageable safety profile in relapsed/refractory setting as well as in first line therapy of high-risk disease. These two combinations are potential new standard treatment options in chronic lymphocytic leukemia. Springer Vienna 2018-06-01 2018 /pmc/articles/PMC6006235/ /pubmed/29983825 http://dx.doi.org/10.1007/s12254-018-0414-0 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Wanner, David
Steurer, Michael
Chronic lymphocytic leukemia at ASH 2017
title Chronic lymphocytic leukemia at ASH 2017
title_full Chronic lymphocytic leukemia at ASH 2017
title_fullStr Chronic lymphocytic leukemia at ASH 2017
title_full_unstemmed Chronic lymphocytic leukemia at ASH 2017
title_short Chronic lymphocytic leukemia at ASH 2017
title_sort chronic lymphocytic leukemia at ash 2017
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006235/
https://www.ncbi.nlm.nih.gov/pubmed/29983825
http://dx.doi.org/10.1007/s12254-018-0414-0
work_keys_str_mv AT wannerdavid chroniclymphocyticleukemiaatash2017
AT steurermichael chroniclymphocyticleukemiaatash2017

Ejemplares similares